MENDELIKABS

MendeliKABS is the manufacturer of the drug MDK-Nitisinone used to treat hereditary tyrosinemia type 1. Classified as an orphan disease, hereditary tyrosinemia type 1 affects one person out of 200,000 worldwide, but is especially prevalent in Quebec with about one hundred persons affected. This is an inherited condition caused by a defect in the degradation of the amino acid tyrosine. The disease can cause severe liver damage, kidney failure and neurological manifestations... MendeliKABS is dedicated to the treatment of rare diseases. We integrate high-level expertise to offer affordable health solutions for orphan diseases and provide drugs manufacturing facilities in full compliance with international regulations and standards... At MendeliKABS, we believe that the appropriate way to fulfill our commitment to quality is to keep a healthy work environment. This constant quest for an optimum workplace atmosphere has been established around clear ethical rules. A continuous training..

Also known as: MendeliKABS Inc.

Primary location: Canada